Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond SMARCA4 Mutations: A Comprehensive Genomic Analysis.
Auguste A, Blanc-Durand F, Deloger M, Le Formal A, Bareja R, Wilkes DC, Richon C, Brunn B, Caron O, Devouassoux-Shisheboran M, Gouy S, Morice P, Bentivegna E, Sboner A, Elemento O, Rubin MA, Pautier P, Genestie C, Cyrta J, Leary A. Auguste A, et al. Cells. 2020 Jun 19;9(6):1496. doi: 10.3390/cells9061496. Cells. 2020. PMID: 32575483 Free PMC article.
Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer.
Auclin E, Benitez-Montanez J, Tagliamento M, Parisi F, Gorria T, Garcia-Campelo R, Dempsey N, Pinato DJ, Reyes R, Albarrán-Artahona V, Dall'Olio F, Soldato D, Hendriks L, Nana FA, Tonneau M, Lopez-Castro R, Nadal E, Kazandjian S, Muanza T, Blanc-Durand F, Fabre E, Castro N, Arasanz H, Rochand A, Besse B, Routy B, Mezquita L. Auclin E, et al. Lung Cancer. 2023 Apr;178:116-122. doi: 10.1016/j.lungcan.2023.02.002. Epub 2023 Feb 4. Lung Cancer. 2023. PMID: 36812760
Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours.
Genestie C, Blanc-Durand F, Auguste A, Pautier P, Dunant A, Scoazec JY, Gouy S, Morice P, Bentivegna E, Maulard A, LeFormal A, Devouassoux-Shisheboran M, Leary A. Genestie C, et al. Br J Cancer. 2020 Feb;122(4):564-568. doi: 10.1038/s41416-019-0687-z. Epub 2019 Dec 17. Br J Cancer. 2020. PMID: 31844183 Free PMC article.
Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT).
Blanc-Durand F, Lefeuvre-Plesse C, Ray-Coquard I, Chaltiel D, Floquet A, Meriaux É, Berton D, Bello-Roufai D, Guillemet C, Dupre PF, Faller É, Alexandre J, Hardy-Bressard AC, Collard O, Fabbro M, Provansal M, Kalbacher E, Genestie C, Pautier P. Blanc-Durand F, et al. Gynecol Oncol. 2020 Oct;159(1):129-135. doi: 10.1016/j.ygyno.2020.07.019. Epub 2020 Jul 25. Gynecol Oncol. 2020. PMID: 32723678
Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer.
Leary A, Genestie C, Blanc-Durand F, Gouy S, Dunant A, Maulard A, Drusch F, Cheaib B, Michels J, Bentivegna E, LeFormal A, Mesnage S, Morice P, Pautier P, Khairallah AS. Leary A, et al. Cancer Immunol Immunother. 2021 Feb;70(2):519-531. doi: 10.1007/s00262-020-02670-0. Epub 2020 Aug 27. Cancer Immunol Immunother. 2021. PMID: 32852603 Free PMC article.
Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test.
Vasseur D, Sassi H, Bayle A, Tagliamento M, Besse B, Marzac C, Arbab A, Auger N, Cotteret S, Aldea M, Blanc-Durand F, Géraud A, Gazzah A, Loriot Y, Hollebecque A, Martín-Romano P, Ngo-Camus M, Nicotra C, Ponce S, Sakkal M, Caron O, Smolenschi C, Micol JB, Italiano A, Rouleau E, Lacroix L. Vasseur D, et al. Cells. 2022 Jun 11;11(12):1901. doi: 10.3390/cells11121901. Cells. 2022. PMID: 35741030 Free PMC article. Review.
[Immunotherapy in oncogynaecology].
Nay P, Morice P, Blanc-Durand F. Nay P, et al. Bull Cancer. 2023 Apr;110(4):395-401. doi: 10.1016/j.bulcan.2023.01.004. Epub 2023 Feb 8. Bull Cancer. 2023. PMID: 36759214 Review. French.
[Current post-surgical treatment strategies in first-line ovarian cancer].
Ouali K, Michels J, Blanc-Durand F, Leary A, Kfoury M, Genestie C, Morice P, Zaccarini F, Scherrier S, Gouy S, Maulard A, Pautier P. Ouali K, et al. Bull Cancer. 2024 Mar;111(3):267-276. doi: 10.1016/j.bulcan.2023.01.020. Epub 2023 Feb 28. Bull Cancer. 2024. PMID: 36863923 Review. French.
A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.
Blanc-Durand F, Yaniz-Galende E, Llop-Guevara A, Genestie C, Serra V, Herencia-Ropero A, Klein C, Berton D, Lortholary A, Dohollou N, Desauw C, Fabbro M, Malaurie E, Bonichon-Lamaichhane N, Dubot C, Kurtz JE, de Rauglaudre G, Raban N, Chevalier-Place A, Ferron G, Kaminsky MC, Kramer C, Rouleau E, Leary A. Blanc-Durand F, et al. Gynecol Oncol. 2023 Apr;171:106-113. doi: 10.1016/j.ygyno.2023.01.026. Epub 2023 Mar 1. Gynecol Oncol. 2023. PMID: 36868112
33 results